Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates

Table 2 Clinical features of rtA181T mutant and non-mutant rtA181T groups n (%)

Clinical features	rtA181T(n = 56)	Not rtA181T(n = 23)	Statistical value	P-value
Gender (M/F)	48/8	18/5	χ2 = 0.659	0.507
Age (yr, mean ± SD)	43.1 ± 9.3	43.4 ± 11.6	t = 0.132	0.896
End-stage liver disease1	21 (37.5)	11 (47.83)	χ2 = 0.721	0.396
NAFLD	21 (37.5)	9 (39.13)	χ2 = 0.018	0.892
E-antigen (+/–)	27/29	18/5a	χ2 = 6.004	0.023
Genotype (B/C)	7/49	9/14b	χ2 = 7.159	0.007
HBV DNA (log10 copy/mL)	5.16 ± 1.23	5.14 ± 1.25	t = 0.086	0.932
Duration of treatment (mo, mean ± SD)	41.2 ± 10.1	40.8 ± 9.7	t = 0.162	0.872

¹End-stage liver disease: included hepatitis cirrhosis, liver failure, and primary hepatocellular carcinoma.

^aP < 0.05, status of e-antigen in the rtA181T mutant group vs in the not-rtA181T mutant group;

^bP < 0.01, genotype (B/C) in the rtA181T mutant group vs the not-rtA181T mutant group. NAFLD: Non-alcoholic fatty liver disease; HBV: Hepatitis B virus.